Bordeaux, December 3, 2021 - Professor Pierre Jaïs, CEO of the Liryc institute (University Hospital Institute), and Dr. Marc Prikazsky, Chairman and CEO of Ceva Santé Animale (Ceva), signed a fundraising agreement making Ceva one of the five largest donors to the Liryc IHU. This support will strengthen the Institute's research projects and the development of innovative solutions to improve the management of cardiovascular diseases.
© Gautier Dufau
2 Nouvelle-Aquitaine regional flagships work together to boost global One Health strategies
Following the launch of its LIGHT UP YOUR HEART fundraising campaign on September 29, Liryc, the University Hospital Institute of Electrophysiology and Heart Modeling, based in Pessac, France, has received major support from Ceva to pursue and develop its research, innovation and training activities.
Ceva and Liryc share a common desire to create synergies in the search for innovative medical solutions in cardiology for both human and animal health, as part of a broader One Health approach. The objective: to promote a platform of exchanges dedicated to cardiology, stimulating research and medical innovation at the interface between humans and companion animals.
"We are proud to count on the major support of Ceva Santé Animale, an economic flagship of the Nouvelle-Aquitaine region. Getting closer to Ceva is also an opportunity for the institute to join the "One Health" dynamic and thus broaden our vision of medicine and research."
"This partnership marks the beginning of a beautiful story between Ceva and Liryc, two major players in health in Nouvelle-Aquitaine region. Through this partnership, we hope to improve the care of dogs and cats and develop innovative solutions in terms of prevention, diagnosis and treatment of heart disease. We look forward to contributing to improving the interactions between animal and human health to yet more concrete results from the One Health approach that we have been advocating for over 10 years."
Ceva, a pioneer in the collaboration between animal and human health in cardiology
Ceva Santé Animale has a long-standing interest in the "One Health" concept, on which its vision is based, and in the transversal approach to human and animal health. The veterinary laboratory is strongly committed to exchanges between human and animal health professionals, and since 2009 has been organizing a joint human /veterinary medicine symposium in cardiology, which brings together international experts from these disciplines to encourage sharing and innovation.
Ceva CEO, Marc Prikazsky, is also very involved in international think tanks and research groups. Dr. Prikazsky is President of the global animal health association, Health for Animals, and helped to the create the new "One Health" scientific council in Nouvelle-Aquitaine, together with Alain Rousset, President of the Nouvelle-Aquitaine Region.
As an expert in cardiology, Ceva aims to improve the quality of life of dogs and cats suffering from heart disease, extend their lifespan and optimize compliance with treatment thanks to effective, well-tolerated and practical treatments.
Liryc, a global center of expertise in cardiac electrophysiology
Bringing together the best international researchers, physicians and engineers in the field on a technological platform that is unique in the world, Liryc is revolutionizing the treatment and prevention of cardiac rhythm diseases, such as atrial and ventricular fibrillation and heart failure.
This fundraising agreement is part of the Institute's commitment to develop public-private partnerships to promote scientific excellence and medical innovation in the field of cardiac rhythm disorders. It also reflects the development of a collaborative, integrated and systemic approach to push back the frontiers of scientific knowledge, for the benefit of human, animal and environmental public health.
About Ceva Santé Animale
Ceva Santé Animale is the leading veterinary pharmaceutical company in France and the fifth largest in the world. Its driving force is innovation for the health of animals, humans and our environment. The Group develops medicines, vaccines, equipment and services for livestock (ruminants, pigs, poultry) and companion animals.
2020 turnover: €1.3 billion.
Liryc is a unique institute in the world, entirely dedicated to treating heart rhythm diseases. These rhythm disorders are responsible for many cardiovascular diseases, which account for nearly one third of all deaths worldwide.
Liryc is one of the seven university-hospital institutes (IHU) created by the French Government as part of the Investments for the Future Program. The aim is to foster medical research and innovation in France. Liryc’s founding members are the University of Bordeaux, Bordeaux University Hospital, Inria and the Regional Council of Nouvelle-Aquitaine. Liryc has four main missions: research, innovation, care and training. It aims to understand the mechanisms involved in cardiac electrical diseases in order to develop better therapeutic and diagnostic tools to improve patients’ care and to promote the acquired knowledge.
>> Download the PDF version: